HIK

Hikma Pharmaceuticals Plc delivers double digit revenue growth & increased profits in FY24

Hikma Pharmaceuticals reports strong 2024 results, with double-digit revenue growth, increased profits, and strategic acquisitions fueling optimism for 2025...

Hikma enhances Injectables pipeline and manufacturing capabilities with Xellia acquisition

Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities...

Hikma Pharmaceuticals PLC provides Trading Update and Future Growth Outlook

Hikma Pharmaceuticals PLC provides a trading update ahead of its Annual General Meeting. CEO Riad Mishlawi highlights strong growth and momentum across the Group in 2024...
Search

Funds

HIK

Hikma Pharmaceuticals Plc delivers double digit revenue growth & increased profits in FY24

Hikma Pharmaceuticals reports strong 2024 results, with double-digit revenue growth, increased profits, and strategic acquisitions fueling optimism for 2025...

Hikma enhances Injectables pipeline and manufacturing capabilities with Xellia acquisition

Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities...

Hikma Pharmaceuticals PLC provides Trading Update and Future Growth Outlook

Hikma Pharmaceuticals PLC provides a trading update ahead of its Annual General Meeting. CEO Riad Mishlawi highlights strong growth and momentum across the Group in 2024...
Search

Funds

HIK

FTSE 100

Funds